[go: up one dir, main page]

AR032318A1 - Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa - Google Patents

Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Info

Publication number
AR032318A1
AR032318A1 ARP010101735A ARP010101735A AR032318A1 AR 032318 A1 AR032318 A1 AR 032318A1 AR P010101735 A ARP010101735 A AR P010101735A AR P010101735 A ARP010101735 A AR P010101735A AR 032318 A1 AR032318 A1 AR 032318A1
Authority
AR
Argentina
Prior art keywords
halo
disease
useful
ischemia
amino
Prior art date
Application number
ARP010101735A
Other languages
English (en)
Inventor
Margaret L Grapperhaus
James A Sikorski
Alok Awasthi
Jane Wang
Barnett S Pitzele
Donald W Hansen Jr
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR032318A1 publication Critical patent/AR032318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto derivado halogenado del ácido 2-amino-5,6 heptenoico de formula (1), o una sal aceptable para uso farmacéutico del mismo, donde R1 se selecciona del grupo formado por hidrogeno, halo y alquilo que puede ser opcionalmente sustituido por uno o más halo; R2 se selecciona del grupo formado por hidrogeno, halo y alquilo que puede ser opcionalmente sustituido por uno o más halo; y con la condicion de que al menos uno entre R1 o R2 contenga un halo. Se describe la composicion farmacéutica que lo comprende y el uso de dichos compuestos y composiciones en la fabricacion de medicamentos utiles como inhibidores de la Oxido Nítrico Sintetasa. Otras condiciones en las cuales puede ser util la inhibicion del ON incluyen la enfermedad inflamatoria del intestino, la isquemia cardiovascular, la diabetes, la deficiencia cardíaca congestiva, la miocarditis, la arteriosclerosis, la migrana, el glaucoma, el aneurisma aortico, la esofagitis por reflujo, la diarrea, el síndrome del colon irritable, la fibrosis quística, el enfisema, el asma, la bronquieclasis, la hiperalgesia (alodinia), la isquemia cerebral (isquemia focal, ataque trombotico e isquemia global (secundaria a la detencion del corazon)), la esclerosis multiple y otras afecciones del sistema nervioso central mediadas por el ON, por ejemplo, el mal de Parkinson y la enfermedad de Alzheimer. Otras afecciones neurodegenerativas sobre las cuales puede ser util la inhibicion del ON incluyen la degeneracion nerviosa y/o la necrosis nerviosas en trastornos tales como, por ej., la hipoxia, la hipoglucemia, la epilepsia, y en lesiones externas (como por ej., en la médula espinal y en la cabeza), las convulsiones hiperbáricas y la toxicidad por oxígeno, la demencia, por ej. la demencia pre-senil y la demencia relacionada con el SIDA, la corea de Sydenham, la enfermedad de Hunlington, la Esclerosis Lateral Amiotrofica, la enfermedad de Korsakoff, la imbecilidad relacionada con una afeccion en los vasos cerebrales, trastornos del sueno, esquizofrenia, depresion u otros síntomas asociados con el Síndrome Premestrual (PMS), ansiedad y ataque séptico. La inhibicion del oxido nítrico puede tener una funcion también en el tratamiento del dolor, incluyendo dolores somatogénicos (nocioceptivos o neuropáticos), tanto agudos como cronicos. Podría usarse un inhibidor del oxido nítrico en cualquier situacion en la cual se pudiera administrarse un NSAID comun o un analgésico opiáceo. Además, otras afecciones que pueden tratarse inhibiendo la produccion de ON incluyen la tolerancia a los opiáceos en pacientes que necesitan de analgésicos opiáceos de uso prolongado y la tolerancia a la benzodiazepinas en pacientes que toman benzodiazepinas, y otros comportamientos adictivos, por ej. nicotina y trastornos de la alimentacion. Los agentes que inhiben el ON pueden ser utiles también como agentes antibacterianos.
ARP010101735A 2000-04-13 2001-04-11 Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa AR032318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19703200P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
AR032318A1 true AR032318A1 (es) 2003-11-05

Family

ID=22727736

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101735A AR032318A1 (es) 2000-04-13 2001-04-11 Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Country Status (14)

Country Link
US (1) US6465686B2 (es)
EP (1) EP1282413A4 (es)
JP (1) JP2003530435A (es)
KR (1) KR20030040202A (es)
CN (1) CN1437468A (es)
AR (1) AR032318A1 (es)
AU (1) AU2001255391A1 (es)
BR (1) BR0110143A (es)
CA (1) CA2405597A1 (es)
EA (1) EA200201054A1 (es)
MX (1) MXPA02010068A (es)
NZ (1) NZ521879A (es)
WO (1) WO2001078719A1 (es)
ZA (1) ZA200208169B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
WO2003022309A1 (fr) * 2001-09-10 2003-03-20 Ono Pharmaceutical Co., Ltd. Remedes pour maladies allergiques
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
IL164826A0 (en) * 2002-05-16 2005-12-18 Pharmacia Corp Methods for the treatment of respiratory diseases and conditions using a selective inos inhibitor
BR0310061A (pt) * 2002-05-16 2005-03-01 Pharmacia Corp Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
ES2307102T3 (es) * 2002-06-19 2008-11-16 Biovitrum Ab (Publ) Piperazinilpirazinas como moduladores del receptor de la serotonina 5-ht2c.
EP1528921A2 (en) * 2002-08-02 2005-05-11 Pharmacia Corporation Methods for treatment and prevention of gastrointestinal conditions
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US8686038B2 (en) 2008-06-19 2014-04-01 The Univsersity of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US9066902B2 (en) 2009-07-31 2015-06-30 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
EP2322514A1 (en) * 2009-11-11 2011-05-18 Bayer Schering Pharma Aktiengesellschaft Homoglutamic acid and glutamic acid derivatives
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren
MX379456B (es) 2015-07-07 2025-03-10 H Lundbeck As Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas.
SG10201913953UA (en) 2015-10-02 2020-03-30 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
WO2020047311A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
CN109021061B (zh) * 2018-09-29 2019-07-12 郭可点 雷公藤甲素靶向前药及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
SI9300616A (en) 1992-11-27 1994-06-30 Wellcome Found Enzyme inhibitors
AU5704594A (en) 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5821267A (en) 1993-10-21 1998-10-13 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
JPH09504028A (ja) 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
WO1995024382A1 (en) * 1994-03-10 1995-09-14 G.D. Searle & Co. L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
ATE188467T1 (de) * 1994-03-24 2000-01-15 Searle & Co Amidino-derivative als no-synthese-inhibitoren
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6011028A (en) 1995-04-20 2000-01-04 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
BR9608133A (pt) 1995-05-10 1999-02-09 Searle & Co Inibidores da sintase de óxido nítrico derivados de amidinas cíclas
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US5830917A (en) 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US6344483B1 (en) 1998-03-11 2002-02-05 G. D. Searle & Co. Halogenated amidino amino acid deviratives useful as nitric oxide synthase inhibitors
MY131964A (en) * 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors

Also Published As

Publication number Publication date
ZA200208169B (en) 2003-10-10
EP1282413A1 (en) 2003-02-12
US6465686B2 (en) 2002-10-15
KR20030040202A (ko) 2003-05-22
NZ521879A (en) 2004-12-24
MXPA02010068A (es) 2003-09-10
BR0110143A (pt) 2005-01-11
EP1282413A4 (en) 2004-12-01
AU2001255391A1 (en) 2001-10-30
WO2001078719A1 (en) 2001-10-25
US20020049202A1 (en) 2002-04-25
EA200201054A1 (ru) 2003-06-26
CN1437468A (zh) 2003-08-20
CA2405597A1 (en) 2001-10-25
JP2003530435A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
AR032318A1 (es) Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
WO2005121130A3 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
US20210087172A1 (en) FACTOR XIIa INHIBITORS
WO2004083167A1 (ja) スルファミド誘導体及びその医薬組成物
CN102159537A (zh) 应用于细菌感染治疗的有机化合物
CN105120866A (zh) 与毒性醛相关的疾病和治疗
JPH07504654A (ja) オキソ及びヒドロキシ置換炭化水素のアミン誘導体
WO2004085433A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
AU2005235248A1 (en) Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists
WO2003070731A3 (en) Azabicyclic compounds for the treatment of disease
US20140371228A1 (en) Novel therapeutic agents
TWI881320B (zh) 含代謝性麩胺酸性受體第２亞型之正別構調節劑或正位激動劑之組合及其用途
ID24231A (id) Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
US12310948B2 (en) Application of monocyclic β-lactam compound in pharmacy
TN2009000205A1 (fr) Analogues de pyrazoles
WO2004069197A3 (en) Novel substituted 2,3-benzodiazepine derivatives
EP3400222B1 (en) Zwitterionic propargyl-linked antifolates useful for treating bacterial infections
KR102418562B1 (ko) 설폰아마이드 유도체 화합물 및 이의 우레아제 억제제로서의 용도
DE69608699T2 (de) Fluorsubstituierte benzoylpropionsaürederivate
WO2006039767A8 (en) Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes
WO2025165846A1 (en) Rhodoquinone mimetics and methods of making and using thereof
WO2023242070A9 (en) Antimicrobial compounds
ATE423093T1 (de) Neue mao-b-hemmer

Legal Events

Date Code Title Description
FB Suspension of granting procedure